| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.99 [0.41, 2.37] | | < 1 | | 96% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.87 [0.46, 1.64] | | < 1 | | 95% | 2 studies (2/-) | 66.7 % | low | not evaluable | high | important | - |
| PFS (extension) | 0.82 [0.35, 1.92] | | < 1 | | 97% | 2 studies (2/-) | 67.7 % | low | not evaluable | high | important | - |
| progression or deaths (PFS) | 0.88 [0.38, 2.06] | | < 1 | | 96% | 2 studies (2/-) | 61.4 % | low | not evaluable | high | important | - |
| objective responses (ORR) | 1.37 [0.24, 7.91] | | > 1 | | 97% | 2 studies (2/-) | 63.9 % | low | not evaluable | high | non important | - |
| objective responses (ORR) (extension) | 0.77 [0.04, 15.30] | | > 1 | | 99% | 2 studies (2/-) | 43.3 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| TRAE (any grade) | 0.54 [0.15, 1.90] | | < 1 | | 90% | 2 studies (2/-) | 83.0 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 0.38 [0.11, 1.29] | | < 1 | | 96% | 2 studies (2/-) | 93.9 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 1.00 [0.06, 15.97] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 0.38 [0.11, 1.30] | | < 1 | | 94% | 2 studies (2/-) | 93.8 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 0.32 [0.12, 0.82] | | < 1 | | 86% | 2 studies (2/-) | 99.1 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.34 [0.03, 3.37] | | < 1 | | 0% | 2 studies (2/-) | 82.0 % | low | not evaluable | high | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 0.64 [0.12, 3.54] | | < 1 | | 33% | 2 studies (2/-) | 69.4 % | low | not evaluable | high | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.79 [0.11, 5.64] | | < 1 | | 0% | 2 studies (2/-) | 59.2 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 0.67 [0.11, 4.12] | | < 1 | | 0% | 2 studies (2/-) | 66.7 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 0.11 [0.05, 0.26] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | non important | - |
| Cough TRAE (grade 3-4) | 4.01 [0.45, 35.95] | | < 1 | | 0% | 2 studies (2/-) | 10.9 % | low | not evaluable | high | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.22 [0.02, 2.08] | | < 1 | | 0% | 2 studies (2/-) | 90.5 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.37 [0.21, 0.64] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 1.00 [0.06, 15.97] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | low | not evaluable | high | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.58 [0.09, 3.80] | | < 1 | | 0% | 2 studies (2/-) | 71.6 % | low | not evaluable | high | non important | - |
| Fatigue TRAE (grade 3-4) | 0.43 [0.10, 1.85] | | < 1 | | 51% | 2 studies (2/-) | 87.0 % | low | not evaluable | high | non important | - |
| Headache TRAE (grade 3-4) | 0.34 [0.03, 3.37] | | < 1 | | 0% | 2 studies (2/-) | 82.0 % | low | not evaluable | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 0.22 [0.02, 2.32] | | < 1 | | 0% | 2 studies (2/-) | 89.4 % | low | not evaluable | high | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.32 [0.03, 3.47] | | < 1 | | 0% | 2 studies (2/-) | 82.4 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.20 [0.04, 0.90] | | < 1 | | 0% | 2 studies (2/-) | 98.2 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.67 [0.05, 8.75] | | < 1 | | 0% | 2 studies (2/-) | 61.9 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 0.43 [0.05, 4.06] | | < 1 | | 77% | 2 studies (2/-) | 76.8 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.31 [0.06, 1.75] | | < 1 | | 76% | 2 studies (2/-) | 90.6 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.65 [0.22, 1.94] | | < 1 | | 78% | 2 studies (2/-) | 77.8 % | low | not evaluable | high | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.64 [0.12, 3.54] | | < 1 | | 33% | 2 studies (2/-) | 69.4 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 1.32 [0.15, 11.31] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | low | not evaluable | high | non important | - |
| Nausea TRAE (grade 3-4) | 0.13 [0.02, 1.03] | | < 1 | | 0% | 2 studies (2/-) | 97.3 % | low | not evaluable | high | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.51 [0.09, 2.98] | | < 1 | | 0% | 2 studies (2/-) | 77.0 % | low | not evaluable | high | non important | - |
| Pruritic rash TRAE (grade 3-4) | 1.00 [0.06, 15.97] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 0.32 [0.06, 1.76] | | < 1 | | 2% | 2 studies (2/-) | 90.4 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.34 [0.03, 3.37] | | < 1 | | 0% | 2 studies (2/-) | 82.0 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 0.14 [0.03, 0.60] | | < 1 | | 0% | 2 studies (2/-) | 99.6 % | low | not evaluable | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.67 [0.05, 8.75] | | < 1 | | 0% | 2 studies (2/-) | 61.9 % | low | not evaluable | high | non important | - |
| Vitiligo TRAE (grade 3-4) | 2.00 [0.18, 22.08] | | < 1 | | 0% | 2 studies (2/-) | 28.8 % | low | not evaluable | high | non important | - |
| Vomiting TRAE (grade 3-4) | 0.30 [0.05, 1.95] | | < 1 | | 18% | 2 studies (2/-) | 89.5 % | low | not evaluable | high | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.67 [0.05, 8.74] | | < 1 | | 0% | 2 studies (2/-) | 61.9 % | low | not evaluable | high | non important | - |
